Please login to the form below

Not currently logged in
Email:
Password:

Recentin goes into phase three studies

Recentin, AstraZeneca's developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer

Recentin, AstraZeneca's (AZ) developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer.

A phase II review by the Horizon Independent Data Monitoring committee concluded that Recentin had met pre-requisite criteria to move into the next stage of trails.

Colorectal cancer is the third most common from of cancer affecting 945,000 people worldwide, with 492,000 being reported annually.

John Patterson, AZ's executive director for development, said: ìGiven there is such a high unmet patient need for more effective treatments in cancer, we are pleased that the Horizon colorectal cancer programme has met its pre-defined criteria to continue into phase III.

However, the National Cancer Institute of Canada Clinical Trails Group (NCIC-CTG) that Recentin will not be continuing into phase III of their trails of Recentin in non-small cell lung cancer (NSCLC).

Patterson said: "AZ supports the NCIC-CTG's recommendation and is working with them to understand the data more fully in NSCLC."

Recentin is being trailed for use in treatment of glioblastoma, and other tumours.

27th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics